Neurodegenerative disease experts

Neurodegeneration research into toxic protein build-up and neuroinflammation, and the gene and cell therapies that slow the loss of cognitive function.

1 expert, updated 22 Oct 2026

What our neurodegenerative disease experts do

Neurodegeneration work at Triple Helix Science targets two mechanisms: the accumulation of toxic proteins in the brain and chronic neuroinflammation. From those targets the company develops gene therapy and stem cell protocols, holds them as protected intellectual property rather than licensing them in, and carries them into human trials. Triple Helix Science reports completing a Phase 1 human trial showing reversal of dementia progression. Protocols are then built for delivery through sovereign health systems at national scale, which is the route by which Triple Helix Science intends genome-based intervention to replace reactive symptom management as the standard of care.

How they work

Neurodegenerative disease experts at Triple Helix Science work from a single position that shapes every protocol: a therapy aimed at the brain alone is incomplete. Toxic protein clearance is developed alongside the autophagy and genomic stability research in the healthy ageing programme, mitochondrial efficiency from the metabolic work, and neuromuscular repair from the muscle biology work, because decline in one organ system accelerates decline in the others. The judgement that matters is which of those systems is driving cognitive loss in a given population. The standard held is years lived in good cognitive health, not years survived.

When to bring them in

Neurodegenerative disease experts at Triple Helix Science are engaged by institutions, not individuals: governments, sovereign health systems and research and pharmaceutical organisations planning around ageing populations. Triple Helix Science does not operate direct to consumer. The circumstances that call for this work are a health system forecasting dementia prevalence a decade ahead, a research programme that needs gene and cell therapy protocols capable of being delivered at national scale, or a decision to shift the national standard of care from managing cognitive symptoms towards predictive, genome-based intervention.

Newsletters

The most recent piece, published under their own names.

Dr Patrick E. Sewell in The Third StrandThe economics of preventive precision medicine22 Oct 2026

Media reaction

Democratising gene and cell therapy

"Gene and cell therapies are no longer a luxury for the elite. The economies of scale are here, and they're here now. These therapies have real use cases, from the most complex cancers to Alzheimer's and neurodegeneration, and they could transform healthcare systems worldwide. For the first time, preventative healthcare can be democratised on a global scale."
Dr Patrick E. SewellDr Patrick E. Sewell, Founder and Chief Science Officer, Triple Helix Science20 Oct 2026
1 of 2

Questions about neurodegenerative disease experts

The questions we get asked most about neurodegeneration, answered plainly.

What is neurodegeneration?
Neurodegeneration is the progressive death of neurons and the loss of memory, reasoning and physical control that follows. Two mechanisms drive much of it: toxic proteins accumulating in and around neurons, and chronic neuroinflammation. Neurodegeneration research at Triple Helix Science targets both of those mechanisms directly, using gene therapy and stem cell science rather than managing symptoms as they appear.
What does working with a neurodegenerative disease expert actually involve?
Work on neurodegeneration at Triple Helix Science runs at institutional scale, with governments, sovereign health systems, research universities and enterprise pharmaceutical organisations rather than with individual patients. Proprietary, IP-protected therapeutic protocols are brought into national and research programmes. Because decline in one organ system accelerates decline in others, brain protocols are built alongside metabolic and muscle biology work rather than in isolation.
How is progress in neurodegeneration work measured?
Neurodegeneration work is judged on the course of the disease itself, whether progression slows, halts or reverses, and whether cognitive function is retained. Triple Helix Science reports a completed Phase 1 human trial showing reversal of dementia progression. Across its programmes the governing measure is healthspan, meaning years lived in good physical and cognitive health, rather than lifespan alone.
Is neurodegeneration the same thing as dementia?
Dementia is a clinical syndrome, the observable loss of memory, reasoning and independence. Neurodegeneration is the biological process underneath it, the progressive loss of neurons driven by toxic protein accumulation and neuroinflammation. Triple Helix Science works at the mechanism level, which is why its protocols address the process rather than the presentation, and why outcomes are read as changes in disease progression.
Who needs a neurodegenerative disease expert, and who does not?
Neurodegeneration expertise is relevant when the problem is population-scale: an ageing population, a rising chronic disease burden, or a pharmaceutical programme that needs gene and cell therapy protocols. Triple Helix Science partners with governments, sovereign health systems, research universities, sovereign wealth funds and pharmaceutical organisations. Triple Helix Science does not operate direct to consumer, so it is not the route for an individual seeking personal treatment.

Contact an expert

Get in touch with an expert on neurodegeneration for comment, an interview or a question.

Straight to the Triple Helix Science press team.